Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker

Yixin Kang; Cheng Ge; Huan Zhang; Saizhe Liu; Hongyang Guo; Junchang Cui

doi:10.2147/IDR.S373082

Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker

Infect Drug Resist. 2022 Aug 12:15:4467-4470. doi: 10.2147/IDR.S373082. eCollection 2022.

Authors

Yixin Kang^#¹, Cheng Ge^#², Huan Zhang³, Saizhe Liu⁴, Hongyang Guo⁴, Junchang Cui¹

Affiliations

¹ Department of Respiratory Diseases, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, 100853, People's Republic of China.
² Department of Cardiology, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, 100853, People's Republic of China.
³ Center of Medicine Clinical Research, the First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, 100853, People's Republic of China.
⁴ Department of Cardiology, the Sixth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, 100853, People's Republic of China.

^# Contributed equally.

Abstract

We report the case of an 87-year-old woman with tuberculous pleurisy. She developed adverse effects in the form of thrombocytopenia and gastrointestinal hemorrhage with isoniazid, and thrombocytopenia with linezolid. Her treatment was switched to contezolid plus cycloserine for a 4-week antibiotic duration, with a favorable outcome.

Keywords: contezolid; tuberculous pleurisy.

Publication types

Case Reports

Grants and funding

This work was supported by the Military biosafety research fund (No. 19SWAQ06) and the “13th Five-Year” Military Key Discipline Construction Project of the PLA Medical College. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.